Cargando…
Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma
BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for ∼5% of all thyroid malignancies. To date, surgery is the first-line therapy with curative intention. However, for advanced MTC, conventional chemotherapeutic agents do not provide convincing results. Therefore, the identification of biomarke...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815780/ https://www.ncbi.nlm.nih.gov/pubmed/26882066 http://dx.doi.org/10.1038/bjc.2016.5 |
_version_ | 1782424625402085376 |
---|---|
author | Werner, Thomas A Tamkan-Ölcek, Yasemin Dizdar, Levent Riemer, Jasmin C Wolf, Achim Cupisti, Kenko Verde, Pablo E Knoefel, Wolfram T Krieg, Andreas |
author_facet | Werner, Thomas A Tamkan-Ölcek, Yasemin Dizdar, Levent Riemer, Jasmin C Wolf, Achim Cupisti, Kenko Verde, Pablo E Knoefel, Wolfram T Krieg, Andreas |
author_sort | Werner, Thomas A |
collection | PubMed |
description | BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for ∼5% of all thyroid malignancies. To date, surgery is the first-line therapy with curative intention. However, for advanced MTC, conventional chemotherapeutic agents do not provide convincing results. Therefore, the identification of biomarkers that can be antagonised by small-molecule therapeutics may lead to novel encouraging treatment options. METHODS: Seventy-nine patients with surgically resected and histologically confirmed MTC were included in this study. Tissue microarrays were constructed to assess the relationship between inhibitor of apoptosis proteins (IAPs) survivin or XIAP expression levels and clinicopathological variables as well as overall survival. RESULTS: High survivin or XIAP expression was associated with an advanced T-stage and metastatic disease. Whereas tissue expression levels of survivin correlated with serum calcitonin levels, XIAP was overexpressed in the subgroup of patients with sporadic MTC. Both IAPs were negatively associated with patient survival in the multivariate Cox regressions analysis (survivin: hazard ratio (HR) 1.62; 95% confidence interval (CI): 1.21–2.16; P=0.001; XIAP: HR 1.78; 95% CI: 1.16–2.72; P=0.008). CONCLUSIONS: Survivin and XIAP demonstrate distinct expression patterns in MTCs, which are associated with advanced disease and poor prognosis. We thus provide first evidence that both IAPs might serve as viable targets in patients with MTC. |
format | Online Article Text |
id | pubmed-4815780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-48157802017-02-16 Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma Werner, Thomas A Tamkan-Ölcek, Yasemin Dizdar, Levent Riemer, Jasmin C Wolf, Achim Cupisti, Kenko Verde, Pablo E Knoefel, Wolfram T Krieg, Andreas Br J Cancer Translational Therapeutics BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for ∼5% of all thyroid malignancies. To date, surgery is the first-line therapy with curative intention. However, for advanced MTC, conventional chemotherapeutic agents do not provide convincing results. Therefore, the identification of biomarkers that can be antagonised by small-molecule therapeutics may lead to novel encouraging treatment options. METHODS: Seventy-nine patients with surgically resected and histologically confirmed MTC were included in this study. Tissue microarrays were constructed to assess the relationship between inhibitor of apoptosis proteins (IAPs) survivin or XIAP expression levels and clinicopathological variables as well as overall survival. RESULTS: High survivin or XIAP expression was associated with an advanced T-stage and metastatic disease. Whereas tissue expression levels of survivin correlated with serum calcitonin levels, XIAP was overexpressed in the subgroup of patients with sporadic MTC. Both IAPs were negatively associated with patient survival in the multivariate Cox regressions analysis (survivin: hazard ratio (HR) 1.62; 95% confidence interval (CI): 1.21–2.16; P=0.001; XIAP: HR 1.78; 95% CI: 1.16–2.72; P=0.008). CONCLUSIONS: Survivin and XIAP demonstrate distinct expression patterns in MTCs, which are associated with advanced disease and poor prognosis. We thus provide first evidence that both IAPs might serve as viable targets in patients with MTC. Nature Publishing Group 2016-02-16 2016-02-04 /pmc/articles/PMC4815780/ /pubmed/26882066 http://dx.doi.org/10.1038/bjc.2016.5 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
spellingShingle | Translational Therapeutics Werner, Thomas A Tamkan-Ölcek, Yasemin Dizdar, Levent Riemer, Jasmin C Wolf, Achim Cupisti, Kenko Verde, Pablo E Knoefel, Wolfram T Krieg, Andreas Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma |
title | Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma |
title_full | Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma |
title_fullStr | Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma |
title_full_unstemmed | Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma |
title_short | Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma |
title_sort | survivin and xiap: two valuable biomarkers in medullary thyroid carcinoma |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815780/ https://www.ncbi.nlm.nih.gov/pubmed/26882066 http://dx.doi.org/10.1038/bjc.2016.5 |
work_keys_str_mv | AT wernerthomasa survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT tamkanolcekyasemin survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT dizdarlevent survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT riemerjasminc survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT wolfachim survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT cupistikenko survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT verdepabloe survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT knoefelwolframt survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma AT kriegandreas survivinandxiaptwovaluablebiomarkersinmedullarythyroidcarcinoma |